•  exploring the science

Therapeutic Response Tracking

Cell-type–specific cfDNA sequencing identies and quantifies burden of cell death across neuronal and glial compartments. Serial blood draws provide a directional, tissue-of-origin signal to follow therapeutic impact over time. Non-invasive, repeatable, and trial-ready.

Contact Us

Our Platform

•  exploring the science

A Platform for Monitoring Neuronal Turnover in Response to Intervention

Resonant provides a GCP platform for tracking CNS cell-type–specific turnover via cfDNA methylation signatures. With a single plasma sample, biopharma teams can monitor changes in neuron- and glia-derived cfDNA to evaluate therapeutic impacts, mechanisms of action, and biological responses.

This platform is designed to support early-phase studies, exploratory endpoints, and non-invasive pharmacodynamic research across Alzheimer’s, Parkinson’s, ALS, and related indications.

Learn More

Use cfDNA to Interrogate Drug Mechanism and Impact

Track Cellular Impact of Novel Therapies

Quantify changes in cfDNA from specific brain cell types as a proxy for neurotoxicity, neuroprotection, or disease modulation.

Characterize Mechanism of Action (MoA)

Differentiate drug effects across dopaminergic, cortical, and glial populations using blood-based, cell-of-origin methylation signals.

Explore Dosing, Timing, and Duration Effects

Assess pre- and post-intervention cfDNA dynamics to inform dosing strategy, treatment timing, and exposure duration.

Biomarker Discovery and Hypothesis Generation

Identify response patterns across individuals or cohorts to guide future biomarker development or trial stratification.

•  Our Approach

Platform Capabilities for Biopharma

Sample-to-Data Support

End-to-end pipelines for preclinical and early-phase human studies

Fully RUO Workflow

Includes cfDNA extraction, prep, sequencing, and deconvolution

Longitudinal Compatibility

Supports baseline, pre/post, and multi-timepoint designs

Actionable Data Outputs

Cell-type percentages, differential plots, time-series visuals, and RUO disease signal call

Combining strength

Partner With Resonant.

We equip biopharma developing neurodegenerative therapeutics with cfDNA tools that reveal early therapy impact, resolve CNS cell-type responses, differentiate candidates, and enable non-invasive, longitudinal tracking—so teams move faster with greater confidence.

contact us
The ScienceIndividualsProvidersBiopharmaAbout Us
Copyright © 2024, All rights reserved

Sign Up For Our Newsletter

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.